Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

Go back to Jefferies Highlights Three Biotech Stocks With Blockbuster Potential

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

October 1, 2026 3:00 PM EDT

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro... More